Halozyme Therapeutics, Inc.
HALO
주식 순위
#1546
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San... Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
주가
$123.84
마지막 동기화: 2026-10-20
시가총액
$14.06B
변동 (1일)
1.09%
변동 (1년)
85.17%
국가
US
거래 Halozyme Therapeutics, Inc. (HALO)
카테고리
Healthcare
Halozyme Therapeutics, Inc. (HALO)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 33.19
Halozyme Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 33.19입니다. 2023년 말 기준 P/E 비율은 17.32였습니다.
Halozyme Therapeutics, Inc.의 P/E 비율 기록 (2001 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 33.19 | 143.13% |
| 2024 | 13.65 | -21.15% |
| 2023 | 17.32 | -55.05% |
| 2022 | 38.52 | 174.31% |
| 2021 | 14.04 | -68.84% |
| 2020 | 45.07 | -227.22% |
| 2019 | -35.42 | 35.59% |
| 2018 | -26.13 | -159.52% |
| 2017 | 43.89 | -459.83% |
| 2016 | -12.20 | -82.10% |
| 2015 | -68.13 | 293.44% |
| 2014 | -17.32 | -14.52% |
| 2013 | -20.26 | 45.54% |
| 2012 | -13.92 | -71.79% |
| 2011 | -49.34 | 251.50% |
| 2010 | -14.04 | 60.96% |
| 2009 | -8.72 | -5.11% |
| 2008 | -9.19 | -58.44% |
| 2007 | -22.11 | -35.28% |
| 2006 | -34.17 | 395.28% |
| 2005 | -6.90 | -19.50% |
| 2004 | -8.57 | -97.66% |
| 2003 | -366.80 | 22.46% |
| 2002 | -299.53 | 132.99% |
| 2001 | -128.56 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 28.78 | -13.28% |
US
|
|
| -28.36 | -185.45% |
US
|
|
| -24.57 | -174.02% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -8.61% |
NL
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.